EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor―A Novel Antibody for Immunohistochemistry or AQUA Technology
Epidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR tyrosine kinase inhibitors (TKI) due to conflicting results, all using antibodies detecting EGFR external domain (ED). We tested the predictive value of...
Saved in:
Published in | Clinical cancer research Vol. 17; no. 24; pp. 7796 - 7807 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
15.12.2011
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Epidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR tyrosine kinase inhibitors (TKI) due to conflicting results, all using antibodies detecting EGFR external domain (ED). We tested the predictive value of EGFR protein expression for response to an EGFR TKI with an antibody that detects the intracellular domain (ID) and compared fluorescence-based Automated QUantitative Analysis (AQUA) technology to immunohistochemistry (IHC).
Specimens from 98 gefitinib-treated NSCLC Japanese patients were evaluated by IHC (n = 98 of 98) and AQUA technology (n = 70 of 98). EGFR ID (5B7)- and ED-specific antibodies (3C6 and 31G7) were compared.
EGFR expression evaluated with 5B7 was significantly higher in responders versus nonresponders to gefitinib both with IHC and with AQUA. ED-specific antibodies did not significantly predict response. Using AQUA and ID-specific antibody resulted in the best prediction performance with a positive and negative predictive value (PPV/NPV) for responders of 50% and 87%, respectively. EGFR expression with ID-specific antibody and AQUA also predicted responders in EGFR-mutated patients. Increased EGFR expression with the ID antibody is associated with increased median progression free survival (PFS; 11.7 months vs. 5.0, log rank, P = 0.034) and overall survival (OS; 38.6 vs. 14.9, P = 0.040) from gefitinib therapy.
EGFR protein expression using an ID-specific antibody specifically predicts response to gefitinib in NSCLC patients, including in EGFR-mutated patients, and increased PFS/OS from gefitinib. These data suggest that the choice of diagnostic antibody and methodology matters to predict response and outcome to specific therapies. The potential clinical application needs further validation. Clin Cancer Res; 17(24); 7796-807. ©2011 AACR. |
---|---|
AbstractList | Epidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR tyrosine kinase inhibitors (TKI) due to conflicting results, all using antibodies detecting EGFR external domain (ED). We tested the predictive value of EGFR protein expression for response to an EGFR TKI with an antibody that detects the intracellular domain (ID) and compared fluorescence-based Automated QUantitative Analysis (AQUA) technology to immunohistochemistry (IHC).
Specimens from 98 gefitinib-treated NSCLC Japanese patients were evaluated by IHC (n = 98 of 98) and AQUA technology (n = 70 of 98). EGFR ID (5B7)- and ED-specific antibodies (3C6 and 31G7) were compared.
EGFR expression evaluated with 5B7 was significantly higher in responders versus nonresponders to gefitinib both with IHC and with AQUA. ED-specific antibodies did not significantly predict response. Using AQUA and ID-specific antibody resulted in the best prediction performance with a positive and negative predictive value (PPV/NPV) for responders of 50% and 87%, respectively. EGFR expression with ID-specific antibody and AQUA also predicted responders in EGFR-mutated patients. Increased EGFR expression with the ID antibody is associated with increased median progression free survival (PFS; 11.7 months vs. 5.0, log rank, P = 0.034) and overall survival (OS; 38.6 vs. 14.9, P = 0.040) from gefitinib therapy.
EGFR protein expression using an ID-specific antibody specifically predicts response to gefitinib in NSCLC patients, including in EGFR-mutated patients, and increased PFS/OS from gefitinib. These data suggest that the choice of diagnostic antibody and methodology matters to predict response and outcome to specific therapies. The potential clinical application needs further validation. Clin Cancer Res; 17(24); 7796-807. ©2011 AACR. INTRODUCTION: Epidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR tyrosine kinase inhibitors (TKI) due to conflicting results, all using antibodies detecting EGFR external domain (ED). We tested the predictive value of EGFR protein expression for response to an EGFR TKI with an antibody that detects the intracellular domain (ID) and compared fluorescence-based Automated QUantitative Analysis (AQUA) technology to immunohistochemistry (IHC). METHODS: Specimens from 98 gefitinib-treated NSCLC Japanese patients were evaluated by IHC (n = 98 of 98) and AQUA technology (n = 70 of 98). EGFR ID (5B7)- and ED-specific antibodies (3C6 and 31G7) were compared. RESULTS: EGFR expression evaluated with 5B7 was significantly higher in responders versus nonresponders to gefitinib both with IHC and with AQUA. ED-specific antibodies did not significantly predict response. Using AQUA and ID-specific antibody resulted in the best prediction performance with a positive and negative predictive value (PPV/NPV) for responders of 50% and 87%, respectively. EGFR expression with ID-specific antibody and AQUA also predicted responders in EGFR-mutated patients. Increased EGFR expression with the ID antibody is associated with increased median progression free survival (PFS; 11.7 months vs. 5.0, log rank, P = 0.034) and overall survival (OS; 38.6 vs. 14.9, P = 0.040) from gefitinib therapy. CONCLUSIONS: EGFR protein expression using an ID-specific antibody specifically predicts response to gefitinib in NSCLC patients, including in EGFR-mutated patients, and increased PFS/OS from gefitinib. These data suggest that the choice of diagnostic antibody and methodology matters to predict response and outcome to specific therapies. The potential clinical application needs further validation. Clin Cancer Res; 17(24); 7796-807. [copy ]2011 AACR. Introduction: Epidermal growth factor receptor (EGFR) protein expression in non–small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR tyrosine kinase inhibitors (TKI) due to conflicting results, all using antibodies detecting EGFR external domain (ED). We tested the predictive value of EGFR protein expression for response to an EGFR TKI with an antibody that detects the intracellular domain (ID) and compared fluorescence-based Automated QUantitative Analysis (AQUA) technology to immunohistochemistry (IHC). Methods: Specimens from 98 gefitinib-treated NSCLC Japanese patients were evaluated by IHC (n = 98 of 98) and AQUA technology (n = 70 of 98). EGFR ID (5B7)- and ED-specific antibodies (3C6 and 31G7) were compared. Results: EGFR expression evaluated with 5B7 was significantly higher in responders versus nonresponders to gefitinib both with IHC and with AQUA. ED-specific antibodies did not significantly predict response. Using AQUA and ID-specific antibody resulted in the best prediction performance with a positive and negative predictive value (PPV/NPV) for responders of 50% and 87%, respectively. EGFR expression with ID-specific antibody and AQUA also predicted responders in EGFR-mutated patients. Increased EGFR expression with the ID antibody is associated with increased median progression free survival (PFS; 11.7 months vs. 5.0, log rank, P = 0.034) and overall survival (OS; 38.6 vs. 14.9, P = 0.040) from gefitinib therapy. Conclusions: EGFR protein expression using an ID-specific antibody specifically predicts response to gefitinib in NSCLC patients, including in EGFR-mutated patients, and increased PFS/OS from gefitinib. These data suggest that the choice of diagnostic antibody and methodology matters to predict response and outcome to specific therapies. The potential clinical application needs further validation. Clin Cancer Res; 17(24); 7796–807. ©2011 AACR. INTRODUCTIONEpidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR tyrosine kinase inhibitors (TKI) due to conflicting results, all using antibodies detecting EGFR external domain (ED). We tested the predictive value of EGFR protein expression for response to an EGFR TKI with an antibody that detects the intracellular domain (ID) and compared fluorescence-based Automated QUantitative Analysis (AQUA) technology to immunohistochemistry (IHC). METHODSSpecimens from 98 gefitinib-treated NSCLC Japanese patients were evaluated by IHC (n = 98 of 98) and AQUA technology (n = 70 of 98). EGFR ID (5B7)- and ED-specific antibodies (3C6 and 31G7) were compared. RESULTSEGFR expression evaluated with 5B7 was significantly higher in responders versus nonresponders to gefitinib both with IHC and with AQUA. ED-specific antibodies did not significantly predict response. Using AQUA and ID-specific antibody resulted in the best prediction performance with a positive and negative predictive value (PPV/NPV) for responders of 50% and 87%, respectively. EGFR expression with ID-specific antibody and AQUA also predicted responders in EGFR-mutated patients. Increased EGFR expression with the ID antibody is associated with increased median progression free survival (PFS; 11.7 months vs. 5.0, log rank, P = 0.034) and overall survival (OS; 38.6 vs. 14.9, P = 0.040) from gefitinib therapy. CONCLUSIONSEGFR protein expression using an ID-specific antibody specifically predicts response to gefitinib in NSCLC patients, including in EGFR-mutated patients, and increased PFS/OS from gefitinib. These data suggest that the choice of diagnostic antibody and methodology matters to predict response and outcome to specific therapies. The potential clinical application needs further validation. Clin Cancer Res; 17(24); 7796-807. ©2011 AACR. |
Author | TRAN, Cindy YOSHIDA, Koichi IKEDA, Norihiko NAGAO, Toshitaka RANGER-MOORE, Jim GAIRE, Fabien WYNES, Murry W KATO, Yasufumi ASUNCION, Bernadette Reyna MATSUBAYASHI, Jun MASCAUX, Celine HIRSCH, Fred R ZHAO, Jason M OHIRA, Tatuso GUSTAVSON, Mark |
AuthorAffiliation | 1 Division of Medical Oncology, University of Colorado Denver, Aurora, CO, USA 5 Ventana Medical System, Inc, Tucson, AZ, USA 6 Division of Pathology, University of Colorado Denver, Aurora, CO, USA 3 Department of Anatomic Pathology, Tokyo Medical University Hospital, Tokyo, Japan 2 Department of Thoracic Surgery, Tokyo Medical University Hospital, Tokyo, Japan 4 HistoRX, Inc, Brandford, CT, USA |
AuthorAffiliation_xml | – name: 5 Ventana Medical System, Inc, Tucson, AZ, USA – name: 2 Department of Thoracic Surgery, Tokyo Medical University Hospital, Tokyo, Japan – name: 3 Department of Anatomic Pathology, Tokyo Medical University Hospital, Tokyo, Japan – name: 6 Division of Pathology, University of Colorado Denver, Aurora, CO, USA – name: 1 Division of Medical Oncology, University of Colorado Denver, Aurora, CO, USA – name: 4 HistoRX, Inc, Brandford, CT, USA |
Author_xml | – sequence: 1 givenname: Celine surname: MASCAUX fullname: MASCAUX, Celine organization: Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado, United States – sequence: 2 givenname: Murry W surname: WYNES fullname: WYNES, Murry W organization: Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado, United States – sequence: 3 givenname: Toshitaka surname: NAGAO fullname: NAGAO, Toshitaka organization: Department of Anatomic Pathology, Tokyo Medical University Hospital, Tokyo, Japan – sequence: 4 givenname: Koichi surname: YOSHIDA fullname: YOSHIDA, Koichi organization: Department of Thoracic Surgery, Tokyo Medical University Hospital, Tokyo, Japan – sequence: 5 givenname: Tatuso surname: OHIRA fullname: OHIRA, Tatuso organization: Department of Thoracic Surgery, Tokyo Medical University Hospital, Tokyo, Japan – sequence: 6 givenname: Norihiko surname: IKEDA fullname: IKEDA, Norihiko organization: Department of Thoracic Surgery, Tokyo Medical University Hospital, Tokyo, Japan – sequence: 7 givenname: Fred R surname: HIRSCH fullname: HIRSCH, Fred R organization: Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado, United States – sequence: 8 givenname: Yasufumi surname: KATO fullname: KATO, Yasufumi organization: Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado, United States – sequence: 9 givenname: Cindy surname: TRAN fullname: TRAN, Cindy organization: Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado, United States – sequence: 10 givenname: Bernadette Reyna surname: ASUNCION fullname: ASUNCION, Bernadette Reyna organization: Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado, United States – sequence: 11 givenname: Jason M surname: ZHAO fullname: ZHAO, Jason M organization: Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado, United States – sequence: 12 givenname: Mark surname: GUSTAVSON fullname: GUSTAVSON, Mark organization: HistoRX, Inc, Brandford, Connecticut, United States – sequence: 13 givenname: Jim surname: RANGER-MOORE fullname: RANGER-MOORE, Jim organization: Ventana Medical System, Inc, Tucson, Arizona, United States – sequence: 14 givenname: Fabien surname: GAIRE fullname: GAIRE, Fabien organization: Ventana Medical System, Inc, Tucson, Arizona, United States – sequence: 15 givenname: Jun surname: MATSUBAYASHI fullname: MATSUBAYASHI, Jun organization: Department of Anatomic Pathology, Tokyo Medical University Hospital, Tokyo, Japan |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25349716$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21994417$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kstu1DAUhiNURC_wCCBvEGxS7NjOZYM0iqZlxIjLMF1bjud4YpTYUztTkR0v0afoW_EkOOq0wIaNj33Od375XE6TI-ssJMlLgs8J4eU7gosyxYxm50r5lJAUZ7h6kpwQzouUZjk_ivcH5jg5DeE7xoQRzJ4lxxmpKsZIcZLczS8vVuiLdwMYi-Y_dh5CMM6i-PrkbPqtl12HaojHcm-3qJZWgY8JsDFqCGgFYedsADQ4JKPApLYevQvGAvporIyhhW1NYwbnf_28nUXVG-jQzA6mcZsRaefRou_31rUmDE610EfrRxT9s69XM7QG1VrXue34PHmqZRfgxcGeJVcX83X9IV1-vlzUs2WqOK2GlGmGK0wpFJpXTa6hxCClyhvOCq1kSSinpFFFXulS5k2eK-BSg4wpmjeZomfJ-3vd3b7pYaPADl52YudNL_0onDTi34g1rdi6GxHbnlesiAJvDgLeXe8hDCLWpGIPpQW3D6IiWVZklOWRfPtfktCMlrgsygnl96iK3Q0e9OOHCBbTSohp3GIat6jrVXSJaSVi3qu_q3nMetiBCLw-ADIo2WkfR2zCH45TVhUkp78BMZbFZg |
CODEN | CCREF4 |
CitedBy_id | crossref_primary_10_1158_0008_5472_CAN_20_4048 crossref_primary_10_1097_JTO_0b013e31824fe95a crossref_primary_10_3389_fgene_2019_00121 crossref_primary_10_1038_onc_2014_16 crossref_primary_10_1111_his_13815 crossref_primary_10_1016_j_cllc_2013_08_005 crossref_primary_10_1016_j_path_2012_08_006 crossref_primary_10_1126_scisignal_2005906 crossref_primary_10_1007_s13402_013_0133_9 crossref_primary_10_3390_jpm3030251 crossref_primary_10_7717_peerj_3140 crossref_primary_10_1186_1559_0275_9_5 crossref_primary_10_1158_1535_7163_MCT_16_0243 crossref_primary_10_1016_j_prp_2017_09_021 crossref_primary_10_1097_MPA_0000000000000604 crossref_primary_10_1097_JTO_0b013e318287c224 crossref_primary_10_1016_j_cllc_2014_05_002 crossref_primary_10_4143_crt_2014_118 crossref_primary_10_1002_pmic_201400008 crossref_primary_10_1016_j_lungcan_2013_07_016 crossref_primary_10_1371_journal_pone_0132953 crossref_primary_10_1053_j_seminoncol_2013_12_011 crossref_primary_10_1016_j_mgene_2016_08_011 crossref_primary_10_1002_jcb_29827 crossref_primary_10_1517_17530059_2012_708336 crossref_primary_10_1016_S1470_2045_11_70316_3 |
Cites_doi | 10.1093/jnci/94.11.788 10.1158/1078-0432.CCR-08-0539 10.1038/sj.bjc.6604249 10.1016/S1470-2045(10)70112-1 10.1038/nm791 10.1097/JTO.0b013e3181ccb27b 10.1056/NEJMoa065411 10.1002/cncr.23491 10.1002/cncr.23282 10.1016/j.ejca.2008.10.026 10.1126/science.2885917 10.1309/DT6BJ698LDX2NGGX 10.1016/S1470-2045(11)70184-X 10.1074/jbc.M202823200 10.1097/JTO.0b013e3181f38f57 10.1200/JCO.2005.05.1474 10.1371/journal.pone.0005133 10.5858/133.9.1413 10.1097/PAI.0b013e318195ecaa 10.1093/jnci/djk134 10.1158/1055-9965.EPI-10-0097 10.1016/S1470-2045(09)70364-X 10.1093/jnci/dji112 10.1056/NEJMoa050736 10.1111/j.1365-2559.2006.02513.x 10.1200/JCO.2007.13.0062 10.1093/jnci/94.11.852 10.1158/1078-0432.CCR-06-0913 10.1093/jnci/dji427 10.1200/JCO.2003.11.069 10.1016/S1556-0864(15)30414-7 10.1056/NEJMoa0909530 10.1097/JTO.0b013e3181e9da60 10.1200/JCO.2009.24.3030 10.1038/modpathol.2009.105 10.1200/JCO.2006.06.3958 10.1093/jnci/94.11.855 |
ContentType | Journal Article |
Copyright | 2015 INIST-CNRS 2011 AACR. |
Copyright_xml | – notice: 2015 INIST-CNRS – notice: 2011 AACR. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 7X8 5PM |
DOI | 10.1158/1078-0432.ccr-11-0209 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE Engineering Research Database CrossRef MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1557-3265 1078-0432 |
EndPage | 7807 |
ExternalDocumentID | 10_1158_1078_0432_CCR_11_0209 21994417 25349716 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: P50 CA058187 – fundername: NCI NIH HHS grantid: P50 CA058187-15 – fundername: National Cancer Institute : NCI grantid: P50 CA058187-15 || CA |
GroupedDBID | --- .55 .GJ 08R 18M 1CY 29B 2FS 2WC 34G 39C 3O- 476 4H- 53G 5GY 5RE 5VS 6J9 AAPBV AAUGY ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFFNX AFHIN AFOSN AFRAH AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW C1A CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 H~9 IH2 IQODW J5H KQ8 L7B LSO MVM OHT OK1 P0W P2P QTD RCR RHF RHI RNS SJN TR2 UDS VH1 W2D W8F WHG WOQ X7M XFK XJT YKV ZA5 ZCG ZGI CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QO 8FD FR3 P64 7X8 5PM |
ID | FETCH-LOGICAL-c539t-4f409033e7f59b6fe80eaac6b547fca813531bc769f8a6b66ce5afea033f5b2c3 |
ISSN | 1078-0432 |
IngestDate | Tue Sep 17 21:28:49 EDT 2024 Thu Oct 24 23:38:27 EDT 2024 Sat Aug 17 01:18:50 EDT 2024 Thu Nov 21 21:03:10 EST 2024 Sat Sep 28 07:49:25 EDT 2024 Sun Oct 29 17:08:29 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 24 |
Keywords | Immunohistochemistry Lung disease Respiratory disease Antibody Lung cancer Malignant tumor non-small cell lung carcinoma Gene expression EGFR tyrosine kinase inhibitor Protein Epidermal growth factor receptor Anatomic pathology Technology Bronchus disease Predictive factor Cancer |
Language | English |
License | CC BY 4.0 2011 AACR. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c539t-4f409033e7f59b6fe80eaac6b547fca813531bc769f8a6b66ce5afea033f5b2c3 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Contributed equally |
OpenAccessLink | https://aacrjournals.org/clincancerres/article-pdf/17/24/7796/2002102/7796.pdf |
PMID | 21994417 |
PQID | 1323808786 |
PQPubID | 23462 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3266947 proquest_miscellaneous_912272346 proquest_miscellaneous_1323808786 crossref_primary_10_1158_1078_0432_CCR_11_0209 pubmed_primary_21994417 pascalfrancis_primary_25349716 |
PublicationCentury | 2000 |
PublicationDate | 2011-12-15 |
PublicationDateYYYYMMDD | 2011-12-15 |
PublicationDate_xml | – month: 12 year: 2011 text: 2011-12-15 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Clinical cancer research |
PublicationTitleAlternate | Clin Cancer Res |
PublicationYear | 2011 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 8845302 - Cell Growth Differ. 1995 Oct;6(10):1251-9 12070153 - J Biol Chem. 2002 Aug 23;277(34):30716-23 15870435 - J Natl Cancer Inst. 2005 May 4;97(9):643-55 19692680 - N Engl J Med. 2009 Sep 3;361(10):947-57 20022809 - Lancet Oncol. 2010 Feb;11(2):121-8 18219661 - Cancer. 2008 Mar 1;112(5):1114-21 18442042 - Cancer. 2008 Jun 15;112(12):2765-73 12670887 - Cancer Res. 2003 Apr 1;63(7):1445-8 12048261 - J Natl Cancer Inst. 2002 Jun 5;94(11):788-9 17075123 - J Clin Oncol. 2006 Nov 1;24(31):5034-42 17409968 - J Thorac Oncol. 2006 Oct;1(8):837-46 2907606 - Mol Cell Biol. 1988 Dec;8(12):5570-4 16368942 - J Natl Cancer Inst. 2005 Dec 21;97(24):1808-15 20697298 - J Thorac Oncol. 2010 Oct;5(10):1551-8 2885917 - Science. 1987 Jul 10;237(4811):178-82 19722747 - Arch Pathol Lab Med. 2009 Sep;133(9):1413-9 20573926 - N Engl J Med. 2010 Jun 24;362(25):2380-8 21124078 - J Thorac Oncol. 2010 Dec;5(12):1905-11 12953099 - J Clin Oncol. 2003 Oct 15;21(20):3798-807 19648882 - Mod Pathol. 2009 Oct;22(10):1341-50 16978205 - Histopathology. 2006 Oct;49(4):411-24 18349398 - J Clin Oncol. 2008 Mar 20;26(9):1472-8 20493771 - Lancet Oncol. 2010 Jun;11(6):521-9 12389040 - Nat Med. 2002 Nov;8(11):1323-7 19318915 - Appl Immunohistochem Mol Morphol. 2009 Jul;17(4):329-37 20332259 - Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):982-91 16707368 - Am J Clin Pathol. 2006 May;125(5):682-92 16014883 - N Engl J Med. 2005 Jul 14;353(2):133-44 19415121 - PLoS One. 2009;4(5):e5133 18283321 - Br J Cancer. 2008 Mar 11;98(5):907-14 17442998 - J Clin Oncol. 2007 Apr 20;25(12):1545-52 12048274 - J Natl Cancer Inst. 2002 Jun 5;94(11):855-7 16951222 - Clin Cancer Res. 2006 Sep 1;12(17):5064-73 20038723 - J Clin Oncol. 2010 Feb 10;28(5):744-52 20107425 - J Thorac Oncol. 2010 Apr;5(4):484-90 17314339 - N Engl J Med. 2007 Feb 22;356(8):800-8 17440164 - J Natl Cancer Inst. 2007 Apr 18;99(8):628-38 12048273 - J Natl Cancer Inst. 2002 Jun 5;94(11):852-4 18829515 - Clin Cancer Res. 2008 Oct 1;14(19):6317-23 11406546 - Cancer Res. 2001 Jun 15;61(12):4744-9 20040275 - Discov Med. 2009 Dec;8(43):227-31 19097774 - Eur J Cancer. 2009 Jan;45(2):228-47 Zheng (2022061106522942500_bib21) 2008; 112 Sok (2022061106522942500_bib39) 2006; 12 Zhou (2022061106522942500_bib9) 2011; 12 Miller (2022061106522942500_bib7) 2008; 26 Tsao (2022061106522942500_bib10) 2005; 353 Gustavson (2022061106522942500_bib31) 2009; 133 Cappuzzo (2022061106522942500_bib14) 2005; 97 Travis (2022061106522942500_bib22) 2004 Zheng (2022061106522942500_bib20) 2007; 356 Hirsch (2022061106522942500_bib30) 2003; 21 Di Fiore (2022061106522942500_bib36) 1987; 237 Maemondo (2022061106522942500_bib8) 2010; 362 Clark (2022061106522942500_bib34) 2006; 1 Hirsch (2022061106522942500_bib11) 2006; 24 Mok (2022061106522942500_bib2) 2009 Hirsch (2022061106522942500_bib4) 2008; 14 Badzio (2022061106522942500_bib29) 2010; 5 Scaltriti (2022061106522942500_bib38) 2007; 99 Paik (2022061106522942500_bib44) 2002; 94 Xia (2022061106522942500_bib16) 2002; 277 Kato (2022061106522942500_bib25) 2010; 5 Zujewski (2022061106522942500_bib46) 2002; 94 Gustavson (2022061106522942500_bib32) 2009; 17 Batra (2022061106522942500_bib40) 1995; 6 Taylor (2022061106522942500_bib41) 2006; 49 Segatto (2022061106522942500_bib37) 1988; 8 Chiappori (2022061106522942500_bib42) 2010; 5 Tamura (2022061106522942500_bib5) 2008; 98 Camp (2022061106522942500_bib19) 2002; 8 Sobin (2022061106522942500_bib23) 2009 Nitadori (2022061106522942500_bib27) 2006; 125 Gatzemeier (2022061106522942500_bib15) 2007; 25 McCabe (2022061106522942500_bib18) 2005; 97 Anagnostou (2022061106522942500_bib33) 2010; 19 Roche (2022061106522942500_bib45) 2002; 94 Hirsch (2022061106522942500_bib28) 2008; 112 Eisenhauer (2022061106522942500_bib24) 2009; 45 Molina (2022061106522942500_bib35) 2001; 61 Mitsudomi (2022061106522942500_bib6) 2010; 11 Wynes (2022061106522942500_bib17) 2009 Mok (2022061106522942500_bib1) 2009; 8 Douillard (2022061106522942500_bib12) 2010; 28 Cappuzzo (2022061106522942500_bib13) 2010; 11 Rosell (2022061106522942500_bib3) 2009; 4 Kojika (2022061106522942500_bib26) 2009; 22 Camp (2022061106522942500_bib43) 2003; 63 |
References_xml | – volume: 63 start-page: 1445 year: 2003 ident: 2022061106522942500_bib43 article-title: Quantitative analysis of breast cancer tissue microarrays shows that both high and normal levels of HER2 expression are associated with poor outcome publication-title: Cancer Res contributor: fullname: Camp – volume: 94 start-page: 788 year: 2002 ident: 2022061106522942500_bib46 article-title: “Build quality in”–HER2 testing in the real world publication-title: J Natl Cancer Inst doi: 10.1093/jnci/94.11.788 contributor: fullname: Zujewski – volume: 14 start-page: 6317 year: 2008 ident: 2022061106522942500_bib4 article-title: Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-08-0539 contributor: fullname: Hirsch – volume: 98 start-page: 907 year: 2008 ident: 2022061106522942500_bib5 article-title: Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403) publication-title: Br J Cancer doi: 10.1038/sj.bjc.6604249 contributor: fullname: Tamura – volume: 11 start-page: 521 year: 2010 ident: 2022061106522942500_bib13 article-title: Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(10)70112-1 contributor: fullname: Cappuzzo – volume: 8 start-page: 1323 year: 2002 ident: 2022061106522942500_bib19 article-title: Automated subcellular localization and quantification of protein expression in tissue microarrays publication-title: Nat Med doi: 10.1038/nm791 contributor: fullname: Camp – volume: 5 start-page: 484 year: 2010 ident: 2022061106522942500_bib42 article-title: Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181ccb27b contributor: fullname: Chiappori – year: 2004 ident: 2022061106522942500_bib22 article-title: World Health Organization Classification of Tumors. Pathology and Genetics. Tumors of the Lung, Pleura, Thymus and Heart contributor: fullname: Travis – volume: 356 start-page: 800 year: 2007 ident: 2022061106522942500_bib20 article-title: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa065411 contributor: fullname: Zheng – volume: 112 start-page: 2765 year: 2008 ident: 2022061106522942500_bib21 article-title: Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer publication-title: Cancer doi: 10.1002/cncr.23491 contributor: fullname: Zheng – volume: 112 start-page: 1114 year: 2008 ident: 2022061106522942500_bib28 article-title: Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer publication-title: Cancer doi: 10.1002/cncr.23282 contributor: fullname: Hirsch – volume: 45 start-page: 228 year: 2009 ident: 2022061106522942500_bib24 article-title: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) publication-title: Eur J Cancer doi: 10.1016/j.ejca.2008.10.026 contributor: fullname: Eisenhauer – volume: 237 start-page: 178 year: 1987 ident: 2022061106522942500_bib36 article-title: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells publication-title: Science doi: 10.1126/science.2885917 contributor: fullname: Di Fiore – volume: 125 start-page: 682 year: 2006 ident: 2022061106522942500_bib27 article-title: Immunohistochemical differential diagnosis between large cell neuroendocrine carcinoma and small cell carcinoma by tissue microarray analysis with a large antibody panel publication-title: Am J Clin Pathol doi: 10.1309/DT6BJ698LDX2NGGX contributor: fullname: Nitadori – volume: 12 start-page: 735 year: 2011 ident: 2022061106522942500_bib9 article-title: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study publication-title: Lancet Oncology doi: 10.1016/S1470-2045(11)70184-X contributor: fullname: Zhou – volume: 277 start-page: 30716 year: 2002 ident: 2022061106522942500_bib16 article-title: Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation publication-title: J Biol Chem doi: 10.1074/jbc.M202823200 contributor: fullname: Xia – volume: 5 start-page: 1905 year: 2010 ident: 2022061106522942500_bib29 article-title: Increased insulin-like growth factor 1 receptor protein expression and gene copy number in small cell lung cancer publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181f38f57 contributor: fullname: Badzio – volume: 25 start-page: 1545 year: 2007 ident: 2022061106522942500_bib15 article-title: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial publication-title: J Clin Oncol doi: 10.1200/JCO.2005.05.1474 contributor: fullname: Gatzemeier – volume: 4 start-page: e5133 year: 2009 ident: 2022061106522942500_bib3 article-title: Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression publication-title: PLoS ONE doi: 10.1371/journal.pone.0005133 contributor: fullname: Rosell – volume: 133 start-page: 1413 year: 2009 ident: 2022061106522942500_bib31 article-title: Standardization of HER2 immunohistochemistry in breast cancer by automated quantitative analysis publication-title: Arch Pathol Lab Med doi: 10.5858/133.9.1413 contributor: fullname: Gustavson – volume: 17 start-page: 329 year: 2009 ident: 2022061106522942500_bib32 article-title: Development of an unsupervised pixel-based clustering algorithm for compartmentalization of immunohistochemical expression using Automated QUantitative Analysis publication-title: Appl Immunohistochem Mol Morphol doi: 10.1097/PAI.0b013e318195ecaa contributor: fullname: Gustavson – volume: 99 start-page: 628 year: 2007 ident: 2022061106522942500_bib38 article-title: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djk134 contributor: fullname: Scaltriti – volume: 61 start-page: 4744 year: 2001 ident: 2022061106522942500_bib35 article-title: Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells publication-title: Cancer Res contributor: fullname: Molina – year: 2009 ident: 2022061106522942500_bib23 article-title: TNM classification of malignant tumors, 7th ed contributor: fullname: Sobin – volume: 19 start-page: 982 year: 2010 ident: 2022061106522942500_bib33 article-title: Analytic variability in immunohistochemistry biomarker studies publication-title: Cancer Epidemiol Biomarkers Prev doi: 10.1158/1055-9965.EPI-10-0097 contributor: fullname: Anagnostou – volume: 11 start-page: 121 year: 2010 ident: 2022061106522942500_bib6 article-title: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70364-X contributor: fullname: Mitsudomi – start-page: 361 year: 2009 ident: 2022061106522942500_bib2 article-title: Gefitinib vs carboplatin-placlitaxel in pulmonary adenocarcinoma publication-title: N Engl J Med contributor: fullname: Mok – volume: 97 start-page: 643 year: 2005 ident: 2022061106522942500_bib14 article-title: Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji112 contributor: fullname: Cappuzzo – volume: 353 start-page: 133 year: 2005 ident: 2022061106522942500_bib10 article-title: Erlotinib in lung cancer—molecular and clinical predictors of outcome publication-title: N Engl J Med doi: 10.1056/NEJMoa050736 contributor: fullname: Tsao – volume: 49 start-page: 411 year: 2006 ident: 2022061106522942500_bib41 article-title: Quantification of immunohistochemistry–issues concerning methods, utility and semiquantitative assessment II publication-title: Histopathology doi: 10.1111/j.1365-2559.2006.02513.x contributor: fullname: Taylor – volume: 26 start-page: 1472 year: 2008 ident: 2022061106522942500_bib7 article-title: Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib publication-title: J Clin Oncol doi: 10.1200/JCO.2007.13.0062 contributor: fullname: Miller – volume: 8 start-page: 5570 year: 1988 ident: 2022061106522942500_bib37 article-title: Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene publication-title: Mol Cell Biol contributor: fullname: Segatto – volume: 6 start-page: 1251 year: 1995 ident: 2022061106522942500_bib40 article-title: Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene publication-title: Cell Growth Differ contributor: fullname: Batra – volume: 94 start-page: 852 year: 2002 ident: 2022061106522942500_bib44 article-title: Real-world performance of HER2 testing–National Surgical Adjuvant Breast and Bowel Project experience publication-title: J Natl Cancer Inst doi: 10.1093/jnci/94.11.852 contributor: fullname: Paik – volume: 12 start-page: 5064 year: 2006 ident: 2022061106522942500_bib39 article-title: Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-06-0913 contributor: fullname: Sok – volume: 97 start-page: 1808 year: 2005 ident: 2022061106522942500_bib18 article-title: Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis publication-title: J Natl Cancer Inst doi: 10.1093/jnci/dji427 contributor: fullname: McCabe – volume: 21 start-page: 3798 year: 2003 ident: 2022061106522942500_bib30 article-title: Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis publication-title: J Clin Oncol doi: 10.1200/JCO.2003.11.069 contributor: fullname: Hirsch – volume: 1 start-page: 837 year: 2006 ident: 2022061106522942500_bib34 article-title: Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib publication-title: J Thorac Oncol doi: 10.1016/S1556-0864(15)30414-7 contributor: fullname: Clark – volume: 362 start-page: 2380 year: 2010 ident: 2022061106522942500_bib8 article-title: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR publication-title: N Engl J Med doi: 10.1056/NEJMoa0909530 contributor: fullname: Maemondo – start-page: S503 volume-title: 13th World Conference on Lung Cancer; 2009 year: 2009 ident: 2022061106522942500_bib17 article-title: Comparative analysis and prognostic association of EGFR protein expression with survival using a novel antibody specific for the intracellular domain of EGFR contributor: fullname: Wynes – volume: 5 start-page: 1551 year: 2010 ident: 2022061106522942500_bib25 article-title: Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations publication-title: J Thorac Oncol doi: 10.1097/JTO.0b013e3181e9da60 contributor: fullname: Kato – volume: 8 start-page: 227 year: 2009 ident: 2022061106522942500_bib1 article-title: A small step towards personalized medicine for non-small cell lung cancer publication-title: Discov Med contributor: fullname: Mok – volume: 28 start-page: 744 year: 2010 ident: 2022061106522942500_bib12 article-title: Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial publication-title: J Clin Oncol doi: 10.1200/JCO.2009.24.3030 contributor: fullname: Douillard – volume: 22 start-page: 1341 year: 2009 ident: 2022061106522942500_bib26 article-title: Immunohistochemical differential diagnosis between thymic carcinoma and type B3 thymoma: diagnostic utility of hypoxic marker, GLUT-1, in thymic epithelial neoplasms publication-title: Mod Pathol doi: 10.1038/modpathol.2009.105 contributor: fullname: Kojika – volume: 24 start-page: 5034 year: 2006 ident: 2022061106522942500_bib11 article-title: Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.3958 contributor: fullname: Hirsch – volume: 94 start-page: 855 year: 2002 ident: 2022061106522942500_bib45 article-title: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831 publication-title: J Natl Cancer Inst doi: 10.1093/jnci/94.11.855 contributor: fullname: Roche |
SSID | ssj0014104 |
Score | 2.2719069 |
Snippet | Epidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR tyrosine... Introduction: Epidermal growth factor receptor (EGFR) protein expression in non–small cell lung cancer (NSCLC) is not recommended for predicting response to... INTRODUCTION: Epidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to... INTRODUCTIONEpidermal growth factor receptor (EGFR) protein expression in non-small cell lung cancer (NSCLC) is not recommended for predicting response to EGFR... |
SourceID | pubmedcentral proquest crossref pubmed pascalfrancis |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 7796 |
SubjectTerms | Adult Aged Aged, 80 and over Antibodies Antineoplastic agents Binding Sites Biological and medical sciences Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Data processing Epidermal growth factor receptors Female Fluorescent Antibody Technique - methods Gefitinib Humans Image Processing, Computer-Assisted - methods Immunohistochemistry Immunohistochemistry - methods Kaplan-Meier Estimate Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Male Medical sciences Middle Aged Multivariate Analysis Mutation Non-small cell lung carcinoma Outcome Assessment (Health Care) - statistics & numerical data Pharmacology. Drug treatments Pneumology Prognosis Proportional Hazards Models Protein Kinase Inhibitors - therapeutic use Protein-tyrosine kinase Quinazolines - therapeutic use Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - biosynthesis Receptor, Epidermal Growth Factor - genetics Survival Therapeutic applications Tissue Array Analysis Tumors of the respiratory system and mediastinum |
Title | EGFR Protein Expression in Non-Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor―A Novel Antibody for Immunohistochemistry or AQUA Technology |
URI | https://www.ncbi.nlm.nih.gov/pubmed/21994417 https://search.proquest.com/docview/1323808786 https://search.proquest.com/docview/912272346 https://pubmed.ncbi.nlm.nih.gov/PMC3266947 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbGkBASQlxHuUxG4m1KaRzn9liVjY3RCY1NjKfIcWwt0pZMbYM0nvgP_A7-FPwRzrGdtB1Fgr1ErevYqb7Plxyf8x1CXg2Y9HWQCk8XvvR4KAaeUAHzCgmjnCdRITUGCo8Pot1j_u4kPFlb-7XgtdTM8r78ujKu5DqoQhngilGy_4Fs1ygUwGfAF66AMFz_CePttzuH6OqPGStRtNj6tBrfxYO68j6e47nzCK1z7xs83keEJ-h1UZTow3Fo_WNN8gwY5qa1o0tYNnHnuV9WsMDB_HFa5jDqJ1utW0QAc8lB_UWdofBAmdeFdfncw0CT2sgXyzaJHDq7D2HPfNWA3yojtFGZ0j6YEx7qDNRjMZWisXmQMWx-fox06RIMAE2gl0_9btkQJivU1mcxbXRzXnZ2iYm1847KyonpFp3l1meeDfV0c_MAxYC5M4eqFWXthB4vEJfxhek5jtNoYamPE5tx989lJEyMRcM13h-NDk38ITNSDrMFal2cG24xlFjmruMlUe8P4xHskKOUxzfITVRrxAQPb_b2u6Mu7pscl11nLswMHuH1ygcw8tW2t6W91J0LBOVM23wsq16Yrvr9Lmykju6Ru-4NiA4tne-TNVU9ILfGzsfjIfmBPKSO1XTOagrfOlZTZDVFVlPLatqymrasprOaCmgAW2tZTS2racdq-vPbdzqkhs-05TMFPtNVfKZQjnymcz4_Isc720ejXc8lFfFkGKQzj2uOpslAxTpM80irZKCEkFEe8lhLkWAeGD-XcZTqRER5FEkVCq0E3KLDnMngMVmv6ko9IdQPfO3HuWY6lFwWqWARpn0qApUA0NrvkX4LT3ZhtWMy884dJhlCmyG0GUALRRlC2yObSyB2d7Ew4Kj11iMvW1Qz-ON4ticqVTfTzA9g7z1I4gTq0L_USX3GYhZwqLJhiTDvwDGqR-IlinQVUIV--ZeqPDVq9I7dT6995zNyez7cn5P12aRRL2CnP8s3zUj5DWK0AO8 |
link.rule.ids | 230,314,780,784,885,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=EGFR+Protein+Expression+in+Non-Small+Cell+Lung+Cancer+Predicts+Response+to+an+EGFR+Tyrosine+Kinase+Inhibitor+%E2%80%93+A+Novel+Antibody+for+Immunohistochemistry+or+AQUA+Technology&rft.jtitle=Clinical+cancer+research&rft.au=Mascaux%2C+Celine&rft.au=Wynes%2C+Murry+W.&rft.au=Kato%2C+Yasufumi&rft.au=Tran%2C+Cindy&rft.date=2011-12-15&rft.issn=1078-0432&rft.eissn=1078-0432&rft.volume=17&rft.issue=24&rft.spage=7796&rft.epage=7807&rft_id=info:doi/10.1158%2F1078-0432.CCR-11-0209&rft_id=info%3Apmid%2F21994417&rft.externalDBID=PMC3266947 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |